MX2021009423A - Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). - Google Patents
Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).Info
- Publication number
- MX2021009423A MX2021009423A MX2021009423A MX2021009423A MX2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- jak2 inhibitor
- jak2
- inhibitor
- compositions
- Prior art date
Links
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 title abstract 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1902018A FR3092581A1 (fr) | 2019-02-12 | 2019-02-12 | Formes cristallines d'un inhibiteur de jak2 |
| PCT/US2020/017764 WO2020167844A1 (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009423A true MX2021009423A (es) | 2021-11-17 |
Family
ID=68281482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009423A MX2021009423A (es) | 2019-02-12 | 2020-02-11 | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332706A1 (https=) |
| EP (1) | EP3927704A4 (https=) |
| JP (2) | JP2022520083A (https=) |
| KR (1) | KR20210148110A (https=) |
| CN (1) | CN114026088A (https=) |
| AU (1) | AU2020221796A1 (https=) |
| BR (1) | BR112021015318A2 (https=) |
| EA (1) | EA202192237A1 (https=) |
| FR (1) | FR3092581A1 (https=) |
| IL (1) | IL285427A (https=) |
| MX (1) | MX2021009423A (https=) |
| SG (1) | SG11202108607QA (https=) |
| WO (1) | WO2020167844A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| US12559463B2 (en) * | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| TW201316989A (zh) * | 2011-07-21 | 2013-05-01 | Sanofi Sa | 用於治療真性多血症及原發性血小板過多症之組合物及方法 |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-02-12 FR FR1902018A patent/FR3092581A1/fr active Pending
-
2020
- 2020-02-11 JP JP2021547092A patent/JP2022520083A/ja active Pending
- 2020-02-11 CN CN202080027762.4A patent/CN114026088A/zh active Pending
- 2020-02-11 MX MX2021009423A patent/MX2021009423A/es unknown
- 2020-02-11 KR KR1020217029156A patent/KR20210148110A/ko not_active Ceased
- 2020-02-11 SG SG11202108607QA patent/SG11202108607QA/en unknown
- 2020-02-11 WO PCT/US2020/017764 patent/WO2020167844A1/en not_active Ceased
- 2020-02-11 AU AU2020221796A patent/AU2020221796A1/en not_active Abandoned
- 2020-02-11 EA EA202192237A patent/EA202192237A1/ru unknown
- 2020-02-11 BR BR112021015318-7A patent/BR112021015318A2/pt unknown
- 2020-02-11 EP EP20756422.0A patent/EP3927704A4/en active Pending
- 2020-02-11 US US17/430,148 patent/US20220332706A1/en not_active Abandoned
-
2021
- 2021-08-06 IL IL285427A patent/IL285427A/en unknown
-
2024
- 2024-12-05 JP JP2024212168A patent/JP2025032217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026088A (zh) | 2022-02-08 |
| SG11202108607QA (en) | 2021-09-29 |
| JP2022520083A (ja) | 2022-03-28 |
| BR112021015318A2 (pt) | 2021-10-05 |
| WO2020167844A1 (en) | 2020-08-20 |
| JP2025032217A (ja) | 2025-03-11 |
| FR3092581A1 (fr) | 2020-08-14 |
| AU2020221796A1 (en) | 2021-08-12 |
| IL285427A (en) | 2021-09-30 |
| KR20210148110A (ko) | 2021-12-07 |
| EP3927704A4 (en) | 2022-12-28 |
| US20220332706A1 (en) | 2022-10-20 |
| EP3927704A1 (en) | 2021-12-29 |
| EA202192237A1 (ru) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007576A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2018010427A (es) | Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
| MX386146B (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
| MX2021003450A (es) | Metodos para tratar trastornos mieloproliferativos. | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2022012832A (es) | Formas cristalinas y metodos de produccion de las mismas. | |
| CO2020006542A2 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
| MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). | |
| MX2018011101A (es) | Composiciones farmaceuticas para el tratamiento del cancer. | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof |